MedTrace Logo

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

NCT00062504 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-05-23

No results posted yet for this study

Summary

To analyze the effect of Talampanel on progression free survival in patients with recurrent high grade gliomas.

Conditions

Interventions

DRUG

Talampanel

10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Study Design

Purpose
TREATMENT
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2006-01-31
Completion
2006-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00062504 on ClinicalTrials.gov